Protara Therapeutics, Inc. announced on June 30, 2025, its inclusion as a member of the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on the same day. This addition is a result of the annual reconstitution of the Russell US Indexes, which captures the 4,000 largest U.S. stocks ranked by market capitalization as of April 30, 2025.
The inclusion in the Russell 3000® Index is a reflection of the company's progress in executing its pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations, and the development of its IV Choline Chloride program.
This membership is expected to enhance Protara's visibility within the financial community, particularly among institutional investors who use Russell indices for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against the Russell US Indexes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.